Sanofi SA

Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis

31 May 2023 00:00:00 By Nasdaq GlobeNewswire

Press Release: Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors

25 May 2023 11:10:28 By Nasdaq GlobeNewswire

Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine

21 May 2023 13:17:08 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares – April 2023

17 May 2023 15:01:19 By Nasdaq GlobeNewswire

Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting

12 May 2023 03:50:00 By Nasdaq GlobeNewswire

Sanofi: COMBINED GENERAL MEETING OF MAY 25, 2023 - AVAILABILITY OF PREPARATORY DOCUMENTS

04 May 2023 01:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi completes acquisition of Provention Bio, Inc.

27 Apr 2023 07:40:15 By Nasdaq GlobeNewswire

Press Release: Strong Q1 growth driven by Specialty Care, Vaccines and CHC

27 Apr 2023 00:30:00 By Nasdaq GlobeNewswire

Press Release: Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc.

26 Apr 2023 01:00:00 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - March 2023

19 Apr 2023 14:05:19 By Nasdaq GlobeNewswire